Related Experiment Video

Updated: Dec 16, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.3K

Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance

Shuya Liu1, Saber Imani1, Youcai Deng2

  • 1Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, People's Republic of China.

Oncotargets and Therapy
|July 2, 2020
PubMed

Insights

The interferon (IFN)/Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) pathway promotes cancer radioresistance. Targeting this pathway could improve radiotherapy and chemotherapy efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Interferon (IFN)-mediated Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling is critical for cellular response to ionizing radiation.
  • The IFN/STAT1 pathway has been implicated in mediating tumor radioresistance by suppressing immune responses and activating survival pathways.

Purpose of the Study:

  • To review the oncogenic role of the IFN/STAT1 pathway in cancer radiation sensitization.
  • To explore the IFN/STAT1 pathway as a therapeutic target for overcoming resistance to radiotherapy and chemotherapy.
  • To discuss the role of microRNAs in regulating the IFN/STAT1 pathway.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of signaling pathways involved in radiation response.
  • Exploration of therapeutic targeting strategies.

Main Results:

  • The IFN/STAT1 pathway plays a significant role in promoting radioresistance within the tumor microenvironment.
  • Targeting the IFN/STAT1 pathway presents a potential strategy for enhancing the efficacy of radiation and chemotherapy.
  • MicroRNAs are involved in the regulation of IFN/STAT1 signaling.

Conclusions:

  • Understanding radiation-induced IFN/STAT1 signaling is key to developing novel cancer therapies.
  • Modulating the IFN/STAT1 pathway offers opportunities to improve radio-immunotherapy outcomes in various cancers.
Keywords:
IFN/STAT1interferon-gamma signalingmicroRNAsignal transducer and activator of transcription 1tumor radioresistance

More Related Videos

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

14.1K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

15.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.6K